bioAffinity Technologies

10/30/2026

An indeterminate pulmonary nodule can leave patients with difficult decisions about what comes next.

CyPath® Lung provides additional information to help clinicians assess malignancy risk and decide whether an invasive procedure is appropriate. For patients, having more information can also provide greater confidence in the reason for the next step.

Learn more: https://cypathlung.com/

10/29/2026

During , bioAffinity Technologies (Nasdaq: BIAF) is highlighting the importance of early lung cancer detection, which can lead to curative therapy.

On November 5, the company will join physicians, patients and healthcare providers at the Lung Cancer Initiative of North Carolina’s Battle of the Blues. The event will highlight advances in lung cancer diagnostics and therapies, including findings from major clinical trials that may inform treatment and patient care.

bioAffinity Technologies will share information about CyPath® Lung, its noninvasive test that analyzes cell populations in patient sputum to help physicians assess lung cancer risk in patients with pulmonary nodules. The test returns a result of “Likely” or “Unlikely” for malignancy, providing additional information to help guide decisions about appropriate follow-up and care. These decisions should be based on the patient’s overall clinical evaluation.

Read the announcement: https://bit.ly/3U0eXaA

10/29/2026

We’re looking forward to connecting with the lung cancer care community at Lung Cancer Initiative’s on November 5 in Raleigh, NC.

bioAffinity Technologies will be there to share how physicians are detecting lung cancer at earlier stages when treatment can be curative using CyPath® Lung, our noninvasive test that helps determine the risk of cancer for patients with small pulmonary nodules.

If you’re attending, come say hello and learn more about how CyPath Lung can lead to better patient outcomes.

10/28/2026

As physicians explore how to incorporate CyPath Lung into patient management, bioAffinity Technologies is seeing new opportunities to expand the test’s clinical use.

In a new Proactive interview, CEO Maria Zannes discusses how CyPath Lung can help assess lung cancer risk and inform decisions around invasive biopsy and continued surveillance. She also shares updates on the company’s commercial growth and broader diagnostic strategy.

Watch the interview: https://bit.ly/3WaBVwd

bioAffinity Technologies CEO Maria Zannes joined Steve Darling from Proactive to discuss the company's noninvasive lung cancer detection technology,...

10/27/2026

Sputum can carry clues from the lungs.

CyPath® Lung uses sputum to look at the lung microenvironment by analyzing whole-cell populations. The test uses a fluorescent porphyrin called TCPP, which preferentially binds to cancer and cancer-related cells, along with fluorescent antibodies that identify other cell types.

Automated analysis then looks for predefined features associated with lung cancer.

It is a different way to gather information from the lungs using a sample that patients can collect at home.

Learn more about what CyPath® Lung detects in sputum: https://cypathlung.com/

10/26/2026

An 85-year-old patient was preparing for an invasive biopsy after a pulmonary nodule was identified.

CyPath® Lung provided the physician with additional diagnostic information that supported a decision to monitor the nodule rather than move forward with biopsy. Follow-up imaging showed the nodule had resolved without further intervention.

It is one example of how additional information can help inform individualized decisions around pulmonary nodule management.

Learn more: https://www.cypathlung.com/

10/23/2026

That's a wrap on ! Thank you to everyone who connected with the bioAffinity Technologies team in Phoenix.

At the poster session, the team presented "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma," sharing research on the company's sputum-based test in development to measure lung inflammation in asthma and COPD. The research builds on the same flow cytometry + AI platform behind CyPath® Lung.

Chief Medical Officer Gordon H. Downie, MD, PhD, also led a Learning Theater presentation on the clinical use of CyPath® Lung, addressing the challenges clinicians face in managing pulmonary nodules and the role of the lung microenvironment in lung cancer risk stratification.

We appreciate every conversation and look forward to continuing them.

The asthma and COPD test is investigational and not available for clinical use.

10/21/2026

Join bioAffinity Technologies’ Chief Medical Officer, Dr. Gordon Downie, at today as he leads the discussion in Learning Theater 4 on new perspectives on using CyPath® Lung for lung cancer risk assessment and pulmonary nodule management.

As more pulmonary nodules are identified through screening and incidental findings, CyPath® Lung can help physicians determine which ones need intervention and which can be safely monitored.

Oct. 21 at 12:30 p.m. MT
Learning Theater 4

10/20/2026

Thank you to everyone who stopped by Booth 1278 to connect with the bioAffinity Technologies team during ! We’ve appreciated the thoughtful conversations with attendees about CyPath® Lung and noninvasive lung cancer risk assessment.

You have another opportunity to connect with us tomorrow. Join Chief Medical Officer Dr. Gordon H. Downie, MD, PhD, for a Learning Theater presentation on using CyPath® Lung testing for early lung cancer diagnosis and pulmonary nodule risk stratification. We look forward to continuing the conversation around the role of noninvasive testing in lung cancer care.

Wednesday, October 21 | 12:30–1:15 p.m. MT
Learning Theater 4 | Phoenix Convention Center

10/20/2026

Today at , bioAffinity Technologies will present research on using sputum to measure lung inflammation in asthma, including cellular and soluble protein biomarkers associated with inflammatory pathways and biologic drug targets.

Poster presentation details:
Title: “Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma”

Poster: 3071

Session: Original Investigation / Allergy-Airway

Date: Tuesday, Oct. 20, 2026

Time: 1:45–2:30 p.m.

Location: Phoenix Convention Center